Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

Dan Heo; Minhee Ku; Jung Hoon Kim; Jaemoon Yang; Jin Suck Suh

doi:10.1186/s11671-018-2682-3

Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

Dan Heo, Minhee Ku, Jung Hoon Kim, Jaemoon Yang, Jin Suck Suh

Department of Radiology

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (Apt_HER2-MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of Apt_HER2-MNS were confirmed, and the binding affinity (K_d) onto HER2 protein of Apt_HER2-MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the Apt_HER2-MNS agent in mice that received the NIH3T6.7 cells.

Original language	English
Article number	288
Journal	Nanoscale Research Letters
Volume	13
DOIs	https://doi.org/10.1186/s11671-018-2682-3
Publication status	Published - 2018

Bibliographical note

Funding Information:
This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea.

Funding Information:
The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea.

Funding Information:
The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Publisher Copyright:
© 2018, The Author(s).

All Science Journal Classification (ASJC) codes

Materials Science(all)
Condensed Matter Physics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s11671-018-2682-3

Cite this

@article{bcefbd9714404353a96035ca9b2e68cf,

title = "Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer",

abstract = "The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (AptHER2-MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of AptHER2-MNS were confirmed, and the binding affinity (Kd) onto HER2 protein of AptHER2-MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the AptHER2-MNS agent in mice that received the NIH3T6.7 cells.",

author = "Dan Heo and Minhee Ku and Kim, {Jung Hoon} and Jaemoon Yang and Suh, {Jin Suck}",

note = "Funding Information: This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. Funding Information: The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. Funding Information: The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

doi = "10.1186/s11671-018-2682-3",

language = "English",

volume = "13",

journal = "Nanoscale Research Letters",

issn = "1931-7573",

publisher = "Springer New York",

}

TY - JOUR

T1 - Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

AU - Heo, Dan

AU - Ku, Minhee

AU - Kim, Jung Hoon

AU - Yang, Jaemoon

AU - Suh, Jin Suck

N1 - Funding Information: This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. Funding Information: The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. Funding Information: The authors gratefully acknowledge the financial support given for this work by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. This study was funded by the National Research Foundation grant funded by the Korean government, Ministry of Education and Science Technology (2015R1A2A1A05001887, 2017R1C1B2010867), the Korea government, Ministry of Trade, Industry and Energy (10047677), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI17C2586, H17C1491, H16C0179), funded by the Ministry of Health & Welfare, and by a faculty research grant of Yonsei University College of Medicine for (6-2014-0032, 2014-32-0022), Republic of Korea. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Publisher Copyright: © 2018, The Author(s).

PY - 2018

Y1 - 2018

N2 - The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (AptHER2-MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of AptHER2-MNS were confirmed, and the binding affinity (Kd) onto HER2 protein of AptHER2-MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the AptHER2-MNS agent in mice that received the NIH3T6.7 cells.

AB - The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (AptHER2-MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of AptHER2-MNS were confirmed, and the binding affinity (Kd) onto HER2 protein of AptHER2-MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the AptHER2-MNS agent in mice that received the NIH3T6.7 cells.

UR - http://www.scopus.com/inward/record.url?scp=85053470085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053470085&partnerID=8YFLogxK

U2 - 10.1186/s11671-018-2682-3

DO - 10.1186/s11671-018-2682-3

M3 - Article

AN - SCOPUS:85053470085

SN - 1931-7573

VL - 13

JO - Nanoscale Research Letters

JF - Nanoscale Research Letters

M1 - 288

ER -

Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this